9 min read ·
Why Your Existing Appeal Right Matters More Than AI
Marketplace consumers appeal fewer than 1 in 500 denied claims, yet about 41% are reversed. See what AI can do and map the review path for your plan.
Fewer than 1 in 500 denied Marketplace claims were appealed by consumers, yet insurers reversed roughly 4 in 10 appealed denials. That is the useful verdict: appealing can work, while no reliable, independently validated AI health insurance denial appeal success rate exists. AI may make an appeal easier to prepare, but current evidence does not show that it improves the chance of reversal (KFF).
The distinction matters amid the 2026 attention on insurer automation. Cigna faces a $12.8 million lawsuit concerning addiction-treatment claim denials, the Minnesota Reformer has examined insurers’ denial “arsenal,” and the Cuban-Andreessen dispute revived debate over AI in coverage decisions. Those developments raise legitimate questions about automated review, but they do not turn an initial denial into a final decision or supply an AI-specific appeal rate.
Why A Denial Often Feels Final
The received wisdom is understandable. Insurers have the policy language, claim systems, medical reviewers, and procedural infrastructure. A consumer may receive a dense notice while dealing with illness, an unpaid bill, or an interruption in treatment. If an algorithm contributed to the decision, appealing can appear even less promising.
The statistics also require restraint. People who appeal may have stronger cases, better records, clinician support, or more money at stake than people who do not. A reversal rate among filed appeals does not show what would happen if every denial were challenged.
The consensus is right about one point: no outcome is guaranteed. Coverage terms, records, deadlines, denial type, plan structure, and review stage all matter. Some services are excluded, and some disputes cannot be cured by a better letter.
But “difficult” is not the same as “effectively final.” KFF found that consumers appealed under 0.2% of 48.3 million denied in-network Marketplace claims in its 2021 dataset. Among the denials that were appealed, insurers upheld 59%, meaning approximately 41% were not upheld. The evidence supports filing a well-grounded appeal more strongly than it supports assuming the first decision will stand.
Choose your plan and denial type; the tool maps the review path and shows the closest available historical benchmark.
Select the facts shown in your notice. Historical percentages describe different groups of past appeals; they are context, not a forecast for your case.
- Copy the exact medical-necessity reason and every cited criterion from the denial.
- Match each criterion to records and ask the treating clinician to verify the clinical explanation.
- File the Marketplace plan’s internal appeal exactly as the notice instructs.
- If the denial is upheld, check the notice and plan materials for eligible state or federal external review.
Why the rate is limited: KFF’s ~41% result covered appealed in-network HealthCare.gov claim denials in aggregate. It was not specific to medical necessity or AI use.
| Plan And Denial | Usual Route To Check | Historical Context | Evidence To Prioritize |
|---|---|---|---|
| Marketplace · Medical necessity | Internal appeal → eligible state or federal external review | ~41% not upheld across appealed in-network Marketplace denials; not type-specific | Criteria, clinical notes, treatment history, clinician rationale |
| Marketplace · Experimental | Internal appeal → eligible state or federal external review | ~41% Marketplace context; not experimental-treatment-specific | Exact exclusion, policy definition, applicable clinical evidence |
| Marketplace · Prior authorization | Correction inquiry or internal appeal → eligible external review | ~41% Marketplace context; not prior-authorization-specific | Request records, referral, submission receipt, clinical criteria |
| Marketplace · Out of network | Internal appeal → external review if eligible | — KFF baseline covered in-network claims | Network status, exception terms, authorization, provider availability |
| Employer · Medical necessity | Internal appeal → external review if eligible; identify funding status | — No employer-plan rate supplied | Criteria, clinical notes, treatment history, clinician rationale |
| Employer · Experimental | Internal appeal → external review if eligible; identify funding status | — No employer-plan rate supplied | Exact exclusion, plan definition, applicable clinical evidence |
| Employer · Prior authorization | Correction inquiry or internal appeal → external review if eligible | — No employer-plan-specific rate supplied | Request records, referral, submission receipt, clinical criteria |
| Employer · Out of network | Internal appeal → external review if eligible; identify funding status | — No employer-plan rate supplied | Network status, exception terms, authorization, provider availability |
| Medicare Advantage · Medical necessity | Plan reconsideration → independent review under notice | — Supplied MA figure is specific to prior authorization | Criteria, clinical notes, treatment history, clinician rationale |
| Medicare Advantage · Experimental | Plan reconsideration → independent review under notice | — No experimental-treatment rate supplied | Coverage rule, exact exclusion, applicable clinical evidence |
| Medicare Advantage · Prior authorization | Plan reconsideration → independent review under notice | Nearly 82% overturned in prior research; study period not supplied | Authorization request, clinical criteria, records, clinician rationale |
| Medicare Advantage · Out of network | Plan reconsideration → independent review under notice | — No out-of-network rate supplied | Network status, plan rules, authorization, provider availability |
Sources: KFF analysis of 2021 HealthCare.gov transparency data; Health Affairs policy analysis reporting prior Medicare Advantage research. Rates are not AI-specific and must not be averaged.
The result is a routing aid, not legal advice or a prediction. Appeal rights and external-review eligibility vary by plan, state, denial reason, and whether an employer plan is self-funded. Use the current denial notice and plan documents for the controlling instructions and deadline.
The 41% Marketplace Baseline Is Not An AI Rate
KFF analyzed insurer-reported CMS transparency data for the 2021 plan year. The data covered in-network claims from non-group qualified health plans offered through HealthCare.gov.
Among 162 issuers with at least 1,000 claims and usable data, insurers denied 48.3 million of 291.6 million in-network claims. The overall denial rate was 16.6%, while individual issuer rates ranged from 2% to 49%.
The reported denial reasons were:
| Reason | Share Of Denials |
|---|---|
| Excluded service | 13.5% |
| Missing authorization or referral | 8.0% |
| Medical necessity | About 2% |
| All other reasons | 76.5% |
Consumers appealed about 90,599 denials—fewer than 0.2% of the 48.3 million denied claims. Insurers upheld 59% of appealed denials, leaving approximately 41% not upheld.
“Not upheld” does not necessarily mean every consumer received full payment or complete approval. The reporting also did not separate results by diagnosis, service, appeal method, or AI use. Issuers with incomplete data or fewer than 1,000 submitted claims were excluded, and the reports were not audited for consistency.
KFF notes that a newer analysis using 2024 data was published in March 2026. Neither the historical nor newer general Marketplace reporting identifies AI-assisted appeals.
A separate report cited 2023 Marketplace data in which insurers upheld 56% of appealed denials, implying that 44% were not upheld. That figure should not be averaged with the 2021 result. The plan years and reporting contexts differ.
Other High Reversal Rates Measure Different Processes
Appeal results can be higher in other programs, but the populations and review stages are not interchangeable.
A policy analysis reported prior research finding that nearly 82% of Medicare Advantage prior-authorization appeals were overturned. The supplied analysis does not identify the underlying study period, and the result is not a benchmark for Marketplace claims, employer plans, or post-service denials (Health Affairs).
Pennsylvania’s state external-review program overturned 50% of denials in its first year, according to WHYY’s January 2025 reporting. National Nurses United has cited reversal rates of 60% to 80% when denials reach independent medical review. The American Medical Association reported in October 2024 that more than 80% of prior-authorization appeals succeed.
These figures support a limited conclusion: denials are regularly reversed in established appeal systems. They do not establish that every denial has a 50% to 80% chance of reversal, and they do not measure AI’s contribution.
| Figure | Setting | What It Measures | AI-Specific? |
|---|---|---|---|
| About 41% | 2021 HealthCare.gov data | Appealed in-network denials not upheld | No |
| 44% | 2023 Marketplace report | Appealed denials not upheld | No |
| Nearly 82% | Medicare Advantage | Prior-authorization appeals overturned | No |
| 80% | Claimable | Company-described appeal success | Vendor claim |
The Marketplace and Medicare Advantage percentages should not be pooled. Doing so would combine different insurance markets, definitions, years, and review procedures into a number with no clear meaning.
The Advertised 80% AI Figure Lacks A Denominator
Claimable advertises an 80% success rate for its appeals. Its service collects denial and insurance information, asks health-related questions, and prepares an appeal using health history, clinical research, and policy details.
Publicly available information does not disclose the sample size, measurement period, case-selection rules, comparison group, or independent audit. It also does not specify whether “success” means full authorization, partial coverage, claim payment, correction of an error, or another favorable change.
A third-party report attributed an approximate 80% figure to the company’s cofounder rather than an independent evaluation. Claimable has also said patients using its model overturned roughly 1,000 denials. That is a count, not a rate, because the total number of relevant cases was not supplied (NBC News).
A credible rate requires a numerator and denominator. Eight hundred favorable decisions could mean 800 of 1,000 completed appeals, 800 of 10,000 people who began intake, or 800 cases selected because they appeared especially promising. Those are materially different results.
A useful evaluation would disclose how many people began intake, how many cases were rejected, how many appeals were generated and submitted, how pending and abandoned cases were counted, and how many received a known decision. It would also identify the plans, denial reasons, treatments, appeal stages, clinician involvement, and definition of success.
Selection matters because a specialized service may support only certain treatments or recognizable denial types. A rate calculated from accepted and completed cases cannot automatically be applied to everyone who attempts to use the service.
A Successful AI-Assisted Appeal Does Not Prove Causation
Conventional appeals succeed without AI. Missing records may arrive, a clinician may document medical necessity, a code may be corrected, or an insurer may identify a processing error.
One reported approval arrived two days after an AI-assisted submission, but the insurer attributed the earlier denials to a processing error involving policy application and specialist assignment. The outcome demonstrates that the individual appeal succeeded, not that AI caused the reversal or that two days is typical (NBC News).
Proving incremental value would require comparing similar AI-assisted and non-AI appeals. The groups would need to be comparable by plan, insurer, treatment, denial reason, appeal stage, available records, clinician participation, timing, and requested remedy.
Independent research has not yet produced rigorous evidence that appeal-generating AI improves accuracy, efficiency, staff experience, or reversal outcomes. Researchers have identified tools that draft letters, assemble payer-specific packets, interpret denial documents, and estimate reversal probability. Those are marketed capabilities, not validated results (Health Affairs).
Public data likewise do not establish whether insurers’ own AI systems improve or worsen coverage outcomes. Researchers have identified possible benefits alongside risks involving limited transparency, inadequate human review, missing patient context, and repetition of flaws in earlier decisions (Stanford Report).
AI Is Most Defensible As A Preparation Tool
AI can still be useful without a proven uplift in reversal rates. Its clearest role is reducing the administrative burden that may prevent an appeal from being filed.
A tool can extract the stated denial reason, cited policy provision, deadline, submission destination, requested records, and described review stages. It can turn those items into a checklist, organize treatment history chronologically, match existing records to listed criteria, and draft a response for review.
The draft should identify the member and denied item, state the requested remedy, answer the insurer’s reason criterion by criterion, and identify each supporting attachment. Precise evidence is more useful than generic language about fairness.
AI should not fill gaps by guessing. Missing clinical support, plan language, or authorization records should be marked as missing until accurate documentation is obtained. A medical-necessity argument should be reviewed by the treating clinician, who can address diagnosis, prior treatment, contraindications, alternatives, and expected benefit.
Every generated assertion requires verification. AI can invent citations, alter dates, introduce unsupported diagnoses, quote the wrong plan, or present irrelevant research as controlling evidence. Users should compare the draft with the denial notice, medical record, and current plan documents before submission. Documentation, deadline compliance, and human review remain necessary even when software prepares the first draft (U.S. News).
The Appeal Should Track The Actual Denial Reason
A focused submission starts with the category of dispute.
For medical necessity, match each stated coverage criterion with clinical records and the treating clinician’s explanation. For experimental-treatment denials, identify the exact policy language and verify that every research citation concerns the relevant condition, treatment, and patient circumstances.
For prior authorization or referral disputes, first determine whether the request was submitted, received, and processed correctly. Ask whether correction or retroactive handling is available under the plan rather than assuming that a long clinical letter is the appropriate remedy.
For out-of-network disputes, verify the network status, applicable exception rules, authorization history, and whether the denial concerns coverage, reimbursement level, or the absence of an eligible in-network provider. The KFF 41% figure concerns in-network Marketplace claims and should not be treated as an out-of-network benchmark.
The requested remedy should be explicit: authorize the treatment, reprocess the identified claim, correct a coding or administrative error, reconsider the decision using attached records, or conduct the next review described in the plan documents.
Submit through the method specified in the notice. Keep the denial, final appeal, attachments, submission confirmation, call notes, correspondence, and final decision. If the internal appeal fails, follow the notice’s instructions for any available external or independent review. Eligibility and administration vary, particularly for employer plans.
Price And Privacy Are Separate From Effectiveness
Consumer AI appeal services have been reported at roughly $40 to $50, while some assistance has been offered without charge. These are dated examples, not universal prices. Comparative evidence showing that a paid service produces better appeal outcomes was not supplied (PBS NewsHour).
A drafting tool may still be worth its price if it helps someone complete an appeal that otherwise would not be filed. That is a workflow benefit, not proof of a higher reversal probability.
Before uploading records, review what medical and insurance information the service collects, how long it retains files, who can access them, whether outside model providers receive the data, and whether submissions are used to train models. Do not assume a service is covered by a particular health-data privacy framework merely because it processes medical information.
Remove identifiers that are unnecessary for drafting, including member numbers, claim numbers, addresses, birth dates, and unrelated medical details. Keep an unredacted copy separately and restore required identifiers only in the final verified submission.
The Evidence Favors Appealing, Not Trusting An AI Percentage
There is no dependable industrywide AI appeal success rate. The advertised 80% figure is a vendor claim without the public methodology needed to evaluate it, while the 41%, 44%, and nearly 82% figures describe conventional appeals in different insurance settings.
The actionable number is the participation gap: fewer than 0.2% of denied Marketplace claims were appealed even though approximately 41% of appealed denials were not upheld. AI’s unproven contribution should not distract from the appeal right that already exists.
Use AI if it makes the paperwork manageable. Base the submission on the actual denial reason, current plan terms, accurate records, clinician input, the stated deadline, and careful human review.